Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase III, Single Institution Randomized Clinical Trial
Abstract
Objective: To determine the long-term outcomes for prostate adenocarcinoma when escalating radiation dose from 70 Gy to 78 Gy. Methods: Between 1993 and 1998, 301 patients with biopsy-proven clinical stage T1b – T3 prostate adenocarcinoma, any prostate-specific antigen (PSA) level, and any Gleason score were randomized to 70 Gy in 35 fractions vs. 78 Gy in 39 fractions photon radiation therapy using a four-field box technique without hormone deprivation therapy. The primary outcome was powered to detect a 15% difference in biochemical and/or clinical failure. Secondary outcomes included survival, prostate cancer mortality, biochemical failure, local failure, nodal failure, distant failure, and secondary malignancy rates. Results: With a median follow-up of 14.3 years, the cumulative incidence of 15-year biochemical and/or clinical failure was 18.9% vs. 12.0% in the 70-Gy vs. 78-Gy arm, respectively (sHR 0.61, 95% CI 0.38 – 0.98; Fine-Gray P=0.042). The 15-year cumulative incidence of distant metastasis was 3.4% vs. 1.1%, respectively (sHR 0.33, 95% CI 0.13 – 0.82; Fine-Gray P=0.018). The 15-year cumulative incidence of prostate cancer-specific mortality was 6.2% vs. 3.2%, respectively (sHR 0.52, 95% CI 0.27 – 0.98; Fine-Gray P=0.045). There were no differences in overall survival (HR 1.10, 95% CI 0.84–1.45; Log Rank P=0.469) or other-cause survival (sHR 1.33, 95% CI 0.99 – 1.79; Fine-Gray P=0.061). Salvage therapy was more common in the 70-Gy arm at 38.7% vs. 21.9% in the…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Preliminary Toxicity Analysis of 3DCRT versus IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial
- Adaptive Radiotherapy for Head and Neck Cancer: Initial Clinical Outcomes from a Prospective Trial
- American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology
- Motion Management Strategies and Technical Issues Associated with Stereotactic Body Radiotherapy of Thoracic and Upper Abdominal Tumors: A Review from NRG Oncology
- High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial
- Highly efficient training, refinement, and validation of a knowledge-based plan quality control system for radiotherapy clinical trials
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.